Germany's Merck shares slip after 2026 guidance at CMD
RefinitivLess than 1 min read
** Shares of Germany's Merck KGaA MRK reverse course and slip around 3% after the pharmaceutical and technology company gave 2026 guidance on its capital markets day
** Shares were up as much as 2% earlier, falling after comments on the CMD call
** A trader says the market did not appreciate comments on 2026
** Merck said it expects organic sales growth in low single digit to mid single digit and about stable EBITDA pre margin for 2026
** For 2026, markets are expected to gradually improve for life science and electronics, while healthcare is expected to temporarily moderate, the company said in a call
Login or create a forever free account to read this news